Skip to main content

CORRECTION article

Front. Pharmacol., 21 May 2020
Sec. Drug Metabolism and Transport

Corrigendum: The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners

  • 1Centre for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
  • 2Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique, Institut National des Sciences Appliquées de Toulouse, Toulouse Biotechnology Institute, Université de Toulouse, Toulouse, France

A Corrigendum on
The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners

by Esteves F, Campelo D, Gomes BC, Urban P, Bozonnet S, Lautier T, Rueff J, Truan G and Kranendonk M (2020). Front. Pharmacol. 11:299. doi: 10.3389/fphar.2020.00299

In the original article, the reference to the study by Gideon et al. (2012) was erroneously used in the second paragraph of the Introduction. It has now been removed.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Reference

Gideon, D. A., Kumari, R., Lynn, A. M., Manoj, K. M. (2012). What is the functional role of n-terminal transmembrane helices in the metabolism mediated by liver microsomal cytochrome P450 and its reductase? Cell Biochem. Biophys. 63, 35–45.

Google Scholar

Keywords: NADPH cytochrome P450 oxidoreductase (CPR), cytochrome P450 monooxygenases (CYP), FMN-domain, binding motifs, redox partner, protein–protein interaction, electron transfer

Citation: Esteves F, Campelo D, Gomes BC, Urban P, Bozonnet S, Lautier T, Rueff J, Truan G and Kranendonk M (2020) Corrigendum: The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners. Front. Pharmacol. 11:773. doi: 10.3389/fphar.2020.00773

Received: 01 April 2020; Accepted: 11 May 2020;
Published: 21 May 2020.

Edited and reviewed by: Miia Turpeinen, Oulu University Hospital, Finland

Copyright © 2020 Esteves, Campelo, Gomes, Urban, Bozonnet, Lautier, Rueff, Truan and Kranendonk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Francisco Esteves, francisco.esteves@nms.unl.pt; Michel Kranendonk, michel.kranendonk@nms.unl.pt

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.